On this basis, we believe that CLCNEC with co mutations of RB1 and TP53 should still be treated with EP regimen chemotherapy for neuroendocrine carcinoma; However, the absence of RB1 and TP53 co mutations in CLCNEC, which is purely treated as neuroendocrine carcinoma, often does not benefit patients due to the dominance of its non small cell carcinoma components, requiring the combination of adjuvant targeted therapy or NSCLC type chemotherapy including NSCLC-GEM/TAX for personalized treatment. The gene discussed is RB1; the disease is small cell carcinoma.